Phase III Study Evaluating the Use of Systemic Chemotherapy and Chemohyperthemia Intraperitoneal Preoperatively (CHIP) and After Maximum Resection of Peritoneal Carcinomatosis Originating With Colorectal Cancer.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Oxaliplatin (Primary) ; Fluorouracil; Folinic acid
Indications Cancer metastases; Carcinoma; Colorectal cancer; Peritoneal cancer
Focus Therapeutic Use
Acronyms PRODIGE 7

Most Recent Events

18 Jan 2021 Results published in the Lancet Oncology
31 May 2020 Results assessing the impact of prior chemotherapy on drug resistance in human tumor organoids isolated from colon cancer patients from Prodige 7 trial presented at the 56th Annual Meeting of the American Society of Clinical Oncology
29 May 2020 Primary endpoint of overall survival has not been met, according to a Nagourney Cancer Institute media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight